Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of XTR003 in Healthy Chinese Volunteers
NCT05136391Phase 1Completed
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XTR003 in coronary artery disease (CAD), sponsored by Sinotau Pharmaceutical Group. Primary endpoint: Safety of XTR003. Started Mar 2021; status: completed.
02
Drugs
XTR003
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05136391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136391.